Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
What The Study Did: This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.
Authors: Eric J. Lenze, M.D., of the Washington University School of Medicine in St. Louis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Media advisory: The full study and editorial are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https:/
JAMA Network Media Relations